Innovent's Jaypirca Approved in China for CLL Treatment Expansion Innovent Biologics has secured approval for Jaypirca in China, marking a significant advancement in treating chronic lymphocytic leukemia and small lymphocytic lymphoma.

Innovent's Jaypirca Approved in China for CLL Treatment Expansion #China #Suzhou #Innovent_Biologics #Chronic_Lymphocytic_Leukemia #Jaypirca

Pirtobrutinib Approved for R/R CLL/SLL After Covalent BTK Therapy The FDA expanded approval of pirtobrutinib (Jaypirca) to adults with R/R CLL or SLL previously treated with a covalent BTK inhibitor.

#Pirtobrutinib (#Jaypirca®), a first-in-class noncovalent #BTKInhibitor, has been approved by the @fda.gov for adults with relapsed or refractory #CLL or #SLL who were previously treated with a covalent #BTKInhibitor, @elilillyandcompany.bsky.social announced.

Read more: https://bit.ly/3YoeE7K

Eli Lilly's Jaypirca Shows Remarkable Efficacy in CLL/SLL Patients, Reducing Progression Risk by 80% Eli Lilly's innovative treatment, Jaypirca, has demonstrated an extraordinary 80% reduction in the risk of progression or death in treatment-naïve CLL/SLL patients. A significant advancement in cancer therapy!

Eli Lilly's Jaypirca Shows Remarkable Efficacy in CLL/SLL Patients, Reducing Progression Risk by 80% #USA #Indianapolis #CLL/SLL #Eli_Lilly #Jaypirca

Lilly's Jaypirca Outperforms Imbruvica in Phase 3 Clinical Trial Lilly's Jaypirca (pirtobrutinib) shows superior efficacy in comparison to Imbruvica (ibrutinib) in a groundbreaking Phase 3 study, with promising results.

Lilly's Jaypirca Outperforms Imbruvica in Phase 3 Clinical Trial #USA #Indianapolis #CLL #Jaypirca #Imbruvica

FDA Approves Expanded Use of Lilly's Jaypirca for CLL/SLL Treatment, Offering Hope to More Patients The FDA has approved an expanded indication for Jaypirca, a groundbreaking therapy for CLL/SLL patients previously treated with BTK inhibitors, potentially aiding numerous individuals.

FDA Approves Expanded Use of Lilly's Jaypirca for CLL/SLL Treatment, Offering Hope to More Patients #United_States #Indianapolis #BTK_Inhibitor #CLL #Jaypirca

Eli Lilly Set to Showcase Key Findings on Jaypirca at ASH 2025 Annual Meeting Eli Lilly will present significant Phase 3 trials data on Jaypirca, focusing on its use in chronic lymphocytic leukemia at the ASH 2025 meeting.

Eli Lilly Set to Showcase Key Findings on Jaypirca at ASH 2025 Annual Meeting #United_States #Orlando #Eli_Lilly #CLL #Jaypirca

Lilly eyes earlier use of blood cancer drug Jaypirca Lilly's fast-growing blood cancer drug Jaypirca could gain more momentum thanks to a trial suggesting it could move into the first-line setting.

#EliLilly's fast-growing #bloodcancer drug #Jaypirca could gain additional momentum thanks to a #newtrial suggesting it could move into the first-line setting.

Lilly’s Jaypirca shows positive results in phase 3 trial - PharmaTimes Pirtobrutinib meets primary endpoint in CLL/SLL study

#oncology #Lilly #LillyOncology #Jaypirca #Pirtobrutinib #primaryendpoint #EliLilly #CLL313 #CLL314 #phase3 #BRUINCLL314trial #chroniclymphocyticleukaemia #CLL #smalllymphocyticlymphoma #SLL #noncovalentBTKinhibitor #Imbruvica #ibrutinib #covalentBTKinhibitor
pharmatimes.com/news/lillys-...

Lilly's Jaypirca: A Breakthrough in Treatment for CLL/SLL Patients Lilly's Jaypirca demonstrates significant improvement in progression-free survival for treatment-naïve CLL/SLL patients in recent clinical trials.

Lilly's Jaypirca: A Breakthrough in Treatment for CLL/SLL Patients #USA #Indianapolis #BTK_Inhibitor #CLL #Jaypirca

Lilly's Jaypirca Shows Promise as Non-Covalent BTK Inhibitor in CLL/SLL Trial Eli Lilly's Jaypirca has met its primary endpoint in a head-to-head trial against Imbruvica for treating CLL/SLL, marking a significant milestone in oncology.

Lilly's Jaypirca Shows Promise as Non-Covalent BTK Inhibitor in CLL/SLL Trial #USA #Indianapolis #BTK_Inhibitor #Lilly #Jaypirca

Innovent and Lilly Collaborate on Jaypirca® Distribution Rights in China Innovent Biologics and Eli Lilly expand their collaboration focused on the distribution of Jaypirca® in Mainland China, enhancing cancer treatment access.

Innovent and Lilly Collaborate on Jaypirca® Distribution Rights in China #China #Suzhou #Innovent_Biologics #Eli_Lilly #Jaypirca